© Borgis - Postępy Nauk Medycznych 3/2016, s. 172-176
Zbigniew Lorenc, *Wiktor Krawczyk
Co nowego w koloproktologii?
What’s new in coloproctology?
Clinical Department of General and Trauma Surgery, Saint's Barbara Specialistic Hospital no 5 in Sosnowiec
Head of Deparment: Zbigniew Lorenc, MD, PhD, Associate Professor
Streszczenie
Ze względu na obserwowany wzrost zapadalności na schorzenia jelita grubego problem ten stanowi bardzo ważny element codziennej pracy większości oddziałów oraz ambulatoriów chirurgicznych. Pojawiają się nowe sposoby postępowania chirurgicznego, w części przypadków wchodząc na stałe do panelu leczniczego, w innych zaś po pierwszych próbach nie uzyskując trwałej akceptacji. Rak jelita grubego (RJG) stanowi obecnie trzecią pozycję wśród wszystkich zachorowań na nowotwory i czwartą w grupie przyczyn zgonów. Znane są czynniki rozwoju RJG zarówno genetyczne, jak i środowiskowe. Wprowadzenie nowych metod diagnostycznych, takich jak TK, NMR, EUS, PET daje nadzieję na zwiększenie odsetka rozpoznania choroby w stadium pozwalającym na uzyskanie najlepszych wyników leczenia. Leczenie operacyjne jest podstawową metodą leczniczą w RJG. Ze względu na rosnącą częstość zachorowań zainteresowanie nieswoistymi chorobami zapalnymi jelit (NZJ) jest wciąż bardzo duże. Postęp, jaki się w tym zakresie dokonuje, dotyczy zarówno leczenia farmakologicznego (nowe preparaty lecznicze), jak i rozpoznania czynników mających wpływ na powstanie i rozwój choroby. W leczeniu szczeliny odbytu problemem może być zła tolerancja farmakoterapii stosowanej w tym schorzeniu, głównie preparatów opartych na nitroglicerynie. Podjęto próby stymulacji nerwu piszczelowego, wprowadzenia odpowiedniej diety w celu poprawy wyników leczenia. W leczeniu przetoki odbytu coraz częściej obserwuje się korzystny efekt po zastosowaniu techniki LIFT, polegającej na podwiązaniu kanału przetoki w przestrzeni międzyzwieraczowej. W leczeniu choroby hemoroidalnej w ostatnich latach rozwijają się techniki oparte na zamykaniu naczyń przy wykorzystaniu techniki dopplerowskiej.
Summary
Because of the growing incidence of large intestine diseases, the issue is a very important element of the daily work of most surgical wards and infirmaries. New surgical procedures are appearing, and some of them become standard procedure, while others fail to gain general acceptance after a few tries. Colorectal cancer (CRCA) is currently the third most popular cancer and the fourth most popular cause of death. Both genetic and environmental factors for CRCA development are known. The introduction of new diagnostic methods such as CT, NMR, PET allows for hope for an increase in the percentage of recognized cases of the disease in a stage, which would make it possible to achieve optimal therapeutic results. Surgery is the basic method of CRCA treatment. Because of the growing frequency of their occurrence, the interest in non-specific inflammatory bowel diseases (IBD) remains very high. Progress in the matter is related to pharmacological therapy (new medicinal products), as well as to recognition of factors, which influence the occurrence and development of the disease. In anal fissure treatment, low tolerance for the pharmacotherapy used against the disease, mainly nitroglycerin-based products, can be a problem. Attempts were made with stimulation the posterior tibial nerve and special diet. In anal fissure therapy, positive results are frequently observed when the LIFT technique is used, which means closure of the fissure channel through the intersphincteric approach. In haemorrhoid disease therapy, techniques based on vessel sealing with the Doppler technique – DGHL, have been developing during the most recent few years.
Because of the growing incidence of large intestine diseases, the issue is a very important element of the daily work of most surgical wards and infirmaries. New surgical procedures are appearing, and some of them become standard procedure, while others fail to gain general acceptance after a few tries.
Colorectal cancer
Colorectal cancer (CRCA) is currently the third most popular cancer and the fourth most popular cause of death (1). Both genetic and environmental factors for CRCA development are known: age over 50 (90% of patients), occurrences of CRCA in the patient’s immediate family, colon polyps, inflammatory bowel diseases, wrong eating habits (obesity, alcohol, tobacco). At the same time, physical activity, the right diet (fruit, fiber, vegetables, fish, D and B6 vitamins, preparations of calcium and magnesium), the use of non-steroidal anti-inflammatory drugs, as well as substitute homeotherapy in postmenopausal women, decrease the risk of CRCA development. During the recent years, there have been some reports about the influence of alcohol consumed on CRCA development. The research results are not clear, yet a certain tendency related to the issue can be observed. In a thesis written with the purpose of researching the correlation between alcohol consumption and development of CRCA in the Mediterranean population, the protective influence of moderate amounts of red wine (up to 35 grams per day) were proven, in the male group of patients, but not in females. However, larger amounts (more than 48 grams per day), mainly in the male group, increased the risk of cancer development. Following the Mediterranean diet was related to a decrease in CRCA development in both sexes (2). Obesity, the rising frequency of which we are also observing in our own country, is not only a higher-risk factor for CRCA development, but also the cause of the increase in percentage of complications in treatment for the disease. This was the conclusion of the authors of a thesis, analyzing the results of therapy of 1048 patients in whose the increased BMI caused worse healing of postoperative wounds and the frequency of eventration occurrence (3). The most important prognostic factor is CRCA advancement at the moment of its recognition, and proper prophylaxis, as well as early diagnosis allow for the improvement of therapeutic results. The most important element of the therapy is surgery, and the implementation of complementary therapy (radio- and chemotherapy) has improved the therapeutic results in the scope of decreasing the percentage of local and distant recurrences, as well as increasing time of survival in advanced cases. In prophylaxis, the basic method is endoscopic screening. Colonoscopy, apart from its diagnostic value, allows for the removal of polyps, which are precancerous conditions for CRCA. However, there are cases of delayed CRCA recognition, after a colonoscopy was performed not very long before, during which no pathological changes were recognized. Literature has introduced the name “interval cancers” for the abovementioned situations. The reason for delayed recognition of “interval cancers” may be the fact that they are small, flat changes, which are not very well visible during endoscopy, especially if the large intestine was not properly prepared or if the endoscopic polypectomy conducted was not thorough enough (4). Some forms of CRCA, which develop in relation to disturbances in DNA repair processes as the reason of cancer development may take on the form of flat changes, quickly-developing polypoid lesions, which develop into cancers during a short period, under 3 years. It has been determined that such forms occur e.g. in the Lynch syndrome, and that they are more frequent in the right half of the colon (5). Similarly, CRCA occurs more frequently in the right half of the colon than in the left half in patients in whom gastroscopy has identified polyps in the duodenum (6). During the recent years it has been observed that CRCA occurrence in the age group of more than 50 years has not decreased, but that it has increased in younger patients, which probably means that the development of the disease is more aggressive in younger patients, however, no clear proof of this thesis has been produced. De Sousa et al. have examined 215 CRCA patients in age groups younger than 50 years (66 people) and older than 50 (149 people) and has not observed any difference in the overall survival rates or in recurrence-free survival in both groups. The independent factors, related to the advancement of the disease, were family history, tobacco smoking, and inflammatory bowel diseases (7). The introduction of new diagnostic methods allows for hope for an increase in the percentage of recognized cases of the disease in a stage, which would make it possible to achieve optimal therapeutic results. One of the important diagnostic factors here, as well as for therapy planning, is the recognition of metastasis in the lymph nodes. Unfortunately, the available diagnostic methods (CT, NMR, and EUS) are characterised by relatively low diagnostic sensitivity in the area of lymph node metastasis recognition. The introduction of PET, a very effective method, which improves the results of tumour diagnosis, local and distant recurrence recognition, allows for hope to improve the diagnostic results also in the area of lymph node metastasis. In a comparative research of PET and CT, Kwak et al. have assessed the usefulness of both methods in the area and has proven a similar effectiveness (87 and 88%, respectively) of both diagnostic methods (8).
Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
- Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
- Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
- Aby kupić kod proszę skorzystać z jednej z poniższych opcji.
Opcja #1
29 zł
Wybieram
- dostęp do tego artykułu
- dostęp na 7 dni
uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony
Opcja #2
69 zł
Wybieram
- dostęp do tego i pozostałych ponad 7000 artykułów
- dostęp na 30 dni
- najpopularniejsza opcja
Opcja #3
129 zł
Wybieram
- dostęp do tego i pozostałych ponad 7000 artykułów
- dostęp na 90 dni
- oszczędzasz 78 zł
Piśmiennictwo
Ahmed S, Johnson K, Ahmed O et al.: Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis 2014; 29: 1031-1042.
Kontou N, Psaltopoulou T, Soupos N et al.: Alcohol consumption and colorectal cancer in a Mediterranean population: a case-control study. Dis Colon Rectum 2012; 55: 703-710.
Amri R, Bordeianou LG, Sylla P et al.: Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancer surgery. Am J Surg 2014; 207: 17-23.
Cisyk AL, Singh H, McManus KJ: Establishing a biological profile for interval cancers. Dig Dis Sci 2014; 59: 2390-2402.
Richter JM, Pino MS, Austin TR: Genetic mechanism in Internal Colon Cancers. Dig Dis Sci 2014; 59: 2255-2263.
Sharaiha RZ, Cohen MS, Reimers L: Sporadic Duodenal Adenoma and association with Colorectal Neoplasia: A Case Control Study. Dig Dis Sci 2014; 59: 2523-2528.
De Sousa JB, Souza CS, Fernandes MB et al.: Do young patients have different clinical presentation of colorectal cancer causing delay in diagnosis. Int J Colorectal Dis 2014; 29: 519-527.
Kwak JY, Kim JS, KIM HJ et al.: Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer. World J Surg 2012; 36: 1898-1905.
Manceau G, d’Annunzio E, Karoui M et al.: Elective subtotal colectomy with ileosigmoid anastomosis for colon cancer preserves bowel function and quality of life. Colorectal Dis 2013; 15: 1078-1085.
Bertelsen CA, Bols B, Ingeholm P et al.: Lymph node metastases in the gastrocolic ligament in patients with colon cancer. Dis Colon Rectum 2014; 57: 839-845.
Rutegard M, Hemmingsson O, Matthiessen P et al.: High tie in anterior resection for rectal cancer confers no increased risk of anastomotic leakage. Br J Surg 2012; 99: 127-132.
Smith JD, Nash GM, Weiser MR et al.: Multivisceral resections for rectal cancer. Br J Surg 2012; 99: 1137-1143.
Moro-Valdezate D, Pla-Marti V, Martin-Arevalo J et al.: Factors related to lymph node harvest: dose a recovery of more than 12 improve the outcome of colorectal cancer? Colorectal Dis 2013; 15: 1257-1266.
Sloothaak DAM, Grewal S, Doornewaard H et al.: Lymph node size as a predictor of lymphatic staging in colonic cancer. Br J Surg 2014; 101: 701-706.
De Raffele E, Mirarchi M, Vaccari S et al.: Intermittent clamping of the hepatic pedicle in simultaneous ultrasonography-guided liver resection and colorectal resection with intestinal anastomosis: it is safe? Int J Colorectal Dis 2014; 29: 1517-1525.
Bower M, Wunderlich Ch, Brown R et al.: Obesity rather than neoadjuvant chemotherapy predicts steatohepatosis in patients with colorectal metastases. Am J Surg 2013; 205: 685-690.
Kim ChH, Huk JW, Kim HJ et al.: Factors influencing oncological outcomes in patients who develop pulmonary metastases after curative resection of colorectal cancer. Dis Colon Rectum 2012; 55: 459-464.
Lan YT, Chang ShCh, Yang ShH et al.: Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. Am J Surg 2014; 207: 922-930.
Jostins L, Ripke S, Weersma RA et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
Regueiro M, Schraut W, Baidoo L et al.: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-450.
Savarino E, Bodini G, Dulbecco P et al.: Adalimubab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease a randomized controlled trial. Am J Gastroenterol 2013; 108: 1731-1742.
Colombel JF, Sandborn WJ, Reinisch W et al.: Infliximab, azathioprine or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395.
Sandborn WJ, Feagan BG, Marano C et al.: Subcutaneous golimumab induces clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
Anderson JL, Edney RJ, Whelan K et al.: Systemic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503-516.
Gross ME, Vogler SA, Mone MC et al.: The importance of extended postoperative venous thromboembolism prophylaxis in IBD: A national surgical quality improvement program analysis. Dis Colon Rectum 2014; 57: 482-489.
Cegielny T, Herman RM, Wałęga P et al.: Surgical and biological treatment of Crohn’s perianal fistulas – results after 1 yr. Colorectal Dis 2012; 12 (suppl. 2): 1-76.
Khaikin M, Bashankaev B, Sands D et al.: The effect of topical anal captopril on resting anal pressure in healthy volunteers: the first human pilot study. Tech Coloproctology 2014; 18: 39-43.
Altunrende B, Sengul E, Arisoy O et al.: Transcutaneous electrical posterior tibial nerve stimulation for chronic anal fissure a preliminary study. Int J Colorectal Dis 2013; 28: 1583-1589.
Carroccio A, Manusueto P, Morfino G et al.: Oligo-antigenic diet in the treatment of chronic anal fissures. Evidence for a relationship between food hypersensitivity and anal fissures. Am J Gastroenterol 2013; 108: 825-832.
Yassin NA, Hammond TM, Lunniss PJ et al.: Ligation of the intersphincteric fistula tract in the management of anal fistula. A systemic review. Colorectal Dis 2013; 15: 527-535.
Blom J, Husberg-Seliberg B, Lindelius A et al.: Results of collagen plug occlusion of anal fistula: a multicenter study of 126 patients. Colorectal Dis 2014 Aug; 16(8): 626-630.
Tan K, Kaur G, Byrne CM et al.: Long-term outcome of the anal fistula plug for anal fistula of cryptoglandular origin. Colorectal Dis 2013; 15: 1510-1514.
Wałęga P, Romaniszyn M, Nowak W et al.: VAAFT: a new minimally invasive method in the diagnostics and treatment of anal fistulas – initial results. Pol Przeg Chir 2014; 86: 7-10.
Prosst RL, Ehni W, Joos AK et al.: The OTSC Proctology clip system for anal fistula closure: first prospective clinical data. Minim Invasive Ther Allied Technol 2013; 22: 255-259.
Pucher P, Sodergren M, Lord A et al.: Clinical outcome following Doppler-guided haemmorhoidal artery ligation: a systemic review. Colorectal Dis 2013 Jun; 15(6): e284-294.
Roka S, Gold D, Wałęga P et al.: DG-RAR for the treatment of symptomatic grade III and grade IV haemorrhoids: a 12-month multi-centre, prospective observational study. Eur Surg 2013; 45: 26-30.